TCMD logo

Tactile Systems Technology, Inc. Stock Price

NasdaqGM:TCMD Community·US$676.2m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 26 Fair Values set on narratives written by author

TCMD Share Price Performance

US$30.68
20.42 (199.03%)
US$39.50
Fair Value
US$30.68
20.42 (199.03%)
22.3% undervalued intrinsic discount
US$39.50
Fair Value
Price US$30.68
AnalystConsensusTarget US$39.50
AnalystLowTarget US$36.00
AnalystHighTarget US$32.00

TCMD Community Narratives

·
Fair Value US$39.5 22.3% undervalued intrinsic discount

TCMD: Market Leadership And Coverage Momentum Will Drive Expansion Into Underserved Patients

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
·
Fair Value US$36 14.8% undervalued intrinsic discount

AI Execution And Policy Dependence Will Pressure Margins And Limit Earnings Upside

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$32 4.1% undervalued intrinsic discount

Lymphedema Tailwinds And AI Workflow Efficiencies Will Drive Significant Long Term Upside

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$32
4.1% undervalued intrinsic discount
Revenue
10.03% p.a.
Profit Margin
9.36%
Future PE
19.54x
Price in 2028
US$40.01

Trending Discussion

Updated Narratives

TCMD logo

TCMD: Index Inclusion And New Respiratory Platform Will Drive Future Upside

Fair Value: US$36 14.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TCMD logo

TCMD: Connected Care Rollout And Buybacks Will Support Future Upside

Fair Value: US$39.5 22.3% undervalued intrinsic discount
12 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TCMD logo

Lymphedema Tailwinds And AI Workflow Efficiencies Will Drive Significant Long Term Upside

Fair Value: US$32 4.1% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and good value.

1 Risk
4 Rewards

Tactile Systems Technology, Inc. Key Details

US$343.5m

Revenue

US$81.1m

Cost of Revenue

US$262.4m

Gross Profit

US$242.1m

Other Expenses

US$20.3m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.90
76.39%
5.91%
0%
View Full Analysis

About TCMD

Founded
1995
Employees
1086
CEO
Sheri Dodd
WebsiteView website
tactilemedical.com

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Recent TCMD News & Updates

Narrative Update Jul 09

TCMD: Index Inclusion And New Respiratory Platform Will Drive Future Upside

Analysts have increased their fair value estimate for Tactile Systems Technology from $16.00 to $36.00, citing updated assumptions around revenue growth, profit margins, and future P/E multiples, which are reflected in recent price target revisions such as the increase highlighted by BTIG. What’s in the News for Tactile Systems Technology Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, with updates focused on patient comfort, ease of use, and connected care capabilities across pediatric and geriatric respiratory patients.

Recent updates

No updates